A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors

Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study

(2017) N. Altorki et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors

(2010) E I Heath et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

(2010) Michael Friedlander et al.   GYNECOLOGIC ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

(2010) Keith C Bible et al.   LANCET ONCOLOGY

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

(2009) Thomas E. Hutson et al.   JOURNAL OF CLINICAL ONCOLOGY